Show simple item record

dc.contributor.authorSofias, Alexandros Marios
dc.contributor.authorToner, Yohana C
dc.contributor.authorMeerwaldt, Anu E
dc.contributor.authorvan Leent, Mandy M T
dc.contributor.authorSoultanidis, Georgios
dc.contributor.authorElschot, Mattijs
dc.contributor.authorGonai, Haruki
dc.contributor.authorGrendstad, Kristin
dc.contributor.authorFlobak, Åsmund
dc.contributor.authorNeckmann, Ulrike
dc.contributor.authorWolowczyk, Camilla
dc.contributor.authorFisher, Elizabeth L
dc.contributor.authorReiner, Thomas
dc.contributor.authorDavies, Catharina de Lange
dc.contributor.authorBjørkøy, Geir
dc.contributor.authorTeunissen, Abraham J P
dc.contributor.authorCano-Ochando, Jordi 
dc.contributor.authorPerez-Medina, Carlos 
dc.contributor.authorMulder, Willem J M
dc.contributor.authorHak, Sjoerd
dc.identifier.citationACS Nano. 2020; 14(7):7832-7846es_ES
dc.description.abstractAlthough the first nanomedicine was clinically approved more than two decades ago, nanoparticles' (NP) in vivo behavior is complex and the immune system's role in their application remains elusive. At present, only passive-targeting nanoformulations have been clinically approved, while more complicated active-targeting strategies typically fail to advance from the early clinical phase stage. This absence of clinical translation is, among others, due to the very limited understanding for in vivo targeting mechanisms. Dynamic in vivo phenomena such as NPs' real-time targeting kinetics and phagocytes' contribution to active NP targeting remain largely unexplored. To better understand in vivo targeting, monitoring NP accumulation and distribution at complementary levels of spatial and temporal resolution is imperative. Here, we integrate in vivo positron emission tomography/computed tomography imaging with intravital microscopy and flow cytometric analyses to study αvβ3-integrin-targeted cyclic arginine-glycine-aspartate decorated liposomes and oil-in-water nanoemulsions in tumor mouse models. We observed that ligand-mediated accumulation in cancerous lesions is multifaceted and identified "NP hitchhiking" with phagocytes to contribute considerably to this intricate process. We anticipate that this understanding can facilitate rational improvement of nanomedicine applications and that immune cell-NP interactions can be harnessed to develop clinically viable nanomedicine-based immunotherapies.es_ES
dc.description.sponsorshipThis work was supported by the Central Norway Regional Health Authority ‘Helse Midt-Norge’ [AMS: PhD stipend (90062100) and travel grant (90284100); SH: researcher grant (90262100)], the National Institutes of Health (WJMM: R01 CA220234, TR: P30 CA00574), the American Heart Association (CPM: 16SDG31390007), the Norwegian Research Council (SH: 230788/F20), and the Tromsø Research Foundation and Trond Mohn Foundation (SH: 180 °N project).es_ES
dc.publisherAmerican Chemical Societyes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.titleTumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking.es_ES
dc.rights.licenseAttribution 4.0 Internacional*
dc.contributor.funderCentral Norway Regional Health Authorityes_ES
dc.contributor.funderNational Institutes of Health (United States)es_ES
dc.contributor.funderAmerican Heart Associationes_ES
dc.contributor.funderNorwegian Research Counciles_ES
dc.contributor.funderTromsø Research Foundationes_ES
dc.contributor.funderTrond Mohn Foundationes_ES
dc.identifier.journalACS nanoes_ES
dc.repisalud.orgCNICNanomedicina e Imagen Moleculares_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 Internacional
This item is licensed under a: Attribution 4.0 Internacional